Key result
Rivaroxaban therapy for DVT linked to life-threatening spontaneous bilateral haemothorax and haemopericardium.
Why the study?
Although the risk of major bleeding with NOACs is low, life-threatening bleeding complications can occur and need to be characterized.
Case Report (n=1)
Rivaroxaban use can lead to life-threatening major haemorrhagic complications, including concomitant spontaneous bilateral haemothorax and haemopericardium.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rare spontaneous haemopericardium with rivaroxaban; hypothesis-generating and should not change practice.
WHAT IS KNOWN AND OBJECTIVE: Although the risk of major bleeding with non-vitamin K antagonist oral anticoagulant (NOAC) is low, life-threatening bleeding can occur. CASE SUMMARY: We report a case of an 81-year-old female with deep vein thrombosis who developed bilateral spontaneous haemothorax and haemopericardium after rivaroxaban therapy. Diagnostic thoracentesis revealed a grossly bloody pleural effusion. She was treated with factor eight inhibitor bypassing agent, but the result was not satisfactory. WHAT IS NEW AND CONCLUSION: To our knowledge, this is the first case report of a concomitant presentation of spontaneous bilateral haemothorax and haemopericardium due to rivaroxaban use. This case highlights the potential risk of major haemorrhagic complication of NOAC, which could be life-threatening and require emergent reversal.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2020) conducted a case report in Deep vein thrombosis (n=1). Rivaroxaban was evaluated on Bilateral spontaneous haemothorax and haemopericardium. Rivaroxaban therapy in an 81-year-old female with deep vein thrombosis was associated with the development of life-threatening spontaneous bilateral haemothorax and haemopericardium.
Synapse has enriched 10 related papers. Consider them for comparative context: